LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing syste… Read more
LivaNova PLC (LIVN) - Net Assets
Latest net assets as of September 2025: $1.16 Billion USD
Based on the latest financial reports, LivaNova PLC (LIVN) has net assets worth $1.16 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.56 Billion) and total liabilities ($1.40 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.16 Billion |
| % of Total Assets | 45.25% |
| Annual Growth Rate | 13.33% |
| 5-Year Change | 19.02% |
| 10-Year Change | -27.12% |
| Growth Volatility | 577.43 |
LivaNova PLC - Net Assets Trend (1992–2024)
This chart illustrates how LivaNova PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LivaNova PLC (1992–2024)
The table below shows the annual net assets of LivaNova PLC from 1992 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.32 Billion | +3.34% |
| 2023-12-31 | $1.28 Billion | +5.80% |
| 2022-12-31 | $1.21 Billion | -6.72% |
| 2021-12-31 | $1.29 Billion | +16.71% |
| 2020-12-31 | $1.11 Billion | -19.83% |
| 2019-12-31 | $1.38 Billion | -7.98% |
| 2018-12-31 | $1.50 Billion | -17.17% |
| 2017-12-31 | $1.82 Billion | +6.35% |
| 2016-12-31 | $1.71 Billion | -5.77% |
| 2015-12-31 | $1.81 Billion | +599.14% |
| 2014-12-31 | $259.10 Million | 0.00% |
| 2013-12-31 | $259.10 Million | +12.86% |
| 2012-12-31 | $229.57 Million | +25.13% |
| 2011-12-31 | $183.47 Million | +4.57% |
| 2010-12-31 | $175.45 Million | +1.26% |
| 2009-12-31 | $173.27 Million | +75.48% |
| 2008-12-31 | $98.74 Million | +530.74% |
| 2007-12-31 | $15.65 Million | +205.67% |
| 2006-12-31 | $-14.81 Million | -419.97% |
| 2005-12-31 | $4.63 Million | -93.88% |
| 2004-12-31 | $75.60 Million | +9.59% |
| 2003-12-31 | $68.98 Million | +2.32% |
| 2002-12-31 | $67.42 Million | +56.70% |
| 2001-12-31 | $43.02 Million | +0.37% |
| 2000-12-31 | $42.87 Million | +57.86% |
| 1999-12-31 | $27.15 Million | -18.70% |
| 1998-12-31 | $33.40 Million | -9.49% |
| 1997-12-31 | $36.90 Million | -24.39% |
| 1996-12-31 | $48.80 Million | +3153.33% |
| 1995-12-31 | $1.50 Million | -78.26% |
| 1994-12-31 | $6.90 Million | -62.70% |
| 1993-12-31 | $18.50 Million | -23.24% |
| 1992-12-31 | $24.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LivaNova PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 88865000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $83.16 Million | 6.30% |
| Other Comprehensive Income | $-80.17 Million | -6.07% |
| Other Components | $2.22 Billion | 168.19% |
| Total Equity | $1.32 Billion | 100.00% |
LivaNova PLC Competitors by Market Cap
The table below lists competitors of LivaNova PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
La Française des Jeux Société anonyme
PINK:LFDJF
|
$3.18 Billion |
|
Century Aluminum Company
NASDAQ:CENX
|
$3.18 Billion |
|
Konfoong Materials International Co Ltd
SHE:300666
|
$3.18 Billion |
|
Volati AB
ST:VOLO-PREF
|
$3.18 Billion |
|
Raiffeisen Bank International AG
PINK:RAIFF
|
$3.18 Billion |
|
Sprott Inc.
NYSE:SII
|
$3.18 Billion |
|
Kuala Lumpur Kepong Berhad
PINK:KLKBF
|
$3.17 Billion |
|
Whitecap Resources Inc.
PINK:SPGYF
|
$3.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LivaNova PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,277,628,000 to 1,320,258,000, a change of 42,630,000 (3.3%).
- Net income of 63,234,000 contributed positively to equity growth.
- Share repurchases of 8,439,000 reduced equity.
- Other comprehensive income decreased equity by 52,287,000.
- Other factors increased equity by 40,122,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $63.23 Million | +4.79% |
| Share Repurchases | $8.44 Million | -0.64% |
| Other Comprehensive Income | $-52.29 Million | -3.96% |
| Other Changes | $40.12 Million | +3.04% |
| Total Change | $- | 3.34% |
Book Value vs Market Value Analysis
This analysis compares LivaNova PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.33x to 2.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1992-12-31 | $3.07 | $62.43 | x |
| 1993-12-31 | $2.07 | $62.43 | x |
| 1994-12-31 | $0.76 | $62.43 | x |
| 1995-12-31 | $0.16 | $62.43 | x |
| 1996-12-31 | $4.05 | $62.43 | x |
| 1997-12-31 | $2.29 | $62.43 | x |
| 1998-12-31 | $1.91 | $62.43 | x |
| 1999-12-31 | $1.50 | $62.43 | x |
| 2001-12-31 | $1.99 | $62.43 | x |
| 2002-12-31 | $3.06 | $62.43 | x |
| 2003-12-31 | $2.69 | $62.43 | x |
| 2004-12-31 | $3.15 | $62.43 | x |
| 2005-12-31 | $0.19 | $62.43 | x |
| 2006-12-31 | $-0.58 | $62.43 | x |
| 2007-12-31 | $0.59 | $62.43 | x |
| 2008-12-31 | $3.59 | $62.43 | x |
| 2009-12-31 | $6.04 | $62.43 | x |
| 2010-12-31 | $6.13 | $62.43 | x |
| 2011-12-31 | $6.48 | $62.43 | x |
| 2012-12-31 | $8.20 | $62.43 | x |
| 2013-12-31 | $9.43 | $62.43 | x |
| 2014-12-31 | $9.43 | $62.43 | x |
| 2015-12-31 | $68.03 | $62.43 | x |
| 2016-12-31 | $34.91 | $62.43 | x |
| 2017-12-31 | $37.43 | $62.43 | x |
| 2018-12-31 | $31.01 | $62.43 | x |
| 2019-12-31 | $28.62 | $62.43 | x |
| 2020-12-31 | $22.83 | $62.43 | x |
| 2021-12-31 | $25.57 | $62.43 | x |
| 2022-12-31 | $22.57 | $62.43 | x |
| 2023-12-31 | $23.57 | $62.43 | x |
| 2024-12-31 | $24.19 | $62.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LivaNova PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.04%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.90x
- Recent ROE (4.79%) is above the historical average (-69.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1992 | -21.16% | -5100.00% | 0.00x | 1.05x | $-7.51 Million |
| 1993 | -31.89% | -1475.00% | 0.02x | 1.07x | $-7.75 Million |
| 1994 | -104.35% | -720.00% | 0.10x | 1.42x | $-7.89 Million |
| 1995 | -673.33% | -721.43% | 0.36x | 2.60x | $-10.25 Million |
| 1996 | -22.95% | -800.00% | 0.03x | 1.08x | $-16.08 Million |
| 1997 | -38.48% | -95.30% | 0.35x | 1.14x | $-17.89 Million |
| 1998 | -37.43% | -41.81% | 0.75x | 1.19x | $-15.84 Million |
| 1999 | -11.24% | -6.38% | 1.20x | 1.47x | $-5.77 Million |
| 2001 | -60.71% | -37.25% | 1.00x | 1.62x | $-30.42 Million |
| 2002 | 7.69% | 4.96% | 1.10x | 1.41x | $-1.56 Million |
| 2003 | 9.80% | 6.10% | 1.17x | 1.37x | $-138.54K |
| 2004 | -16.16% | -11.81% | 1.05x | 1.31x | $-19.78 Million |
| 2005 | -1275.83% | -47.85% | 0.81x | 32.90x | $-59.53 Million |
| 2006 | 0.00% | -39.08% | 0.96x | 0.00x | $-49.70 Million |
| 2007 | -66.02% | -8.52% | 1.15x | 6.72x | $-11.90 Million |
| 2008 | 27.06% | 18.61% | 0.98x | 1.48x | $16.85 Million |
| 2009 | 45.28% | 46.76% | 0.81x | 1.20x | $61.12 Million |
| 2010 | 26.63% | 24.53% | 0.90x | 1.21x | $29.18 Million |
| 2011 | 19.66% | 16.51% | 1.03x | 1.16x | $17.73 Million |
| 2012 | 20.19% | 18.23% | 0.96x | 1.15x | $23.40 Million |
| 2013 | 21.18% | 19.46% | 0.96x | 1.14x | $28.98 Million |
| 2014 | 21.18% | 19.46% | 0.96x | 1.14x | $28.98 Million |
| 2015 | 3.19% | 19.84% | 0.11x | 1.41x | $-123.30 Million |
| 2016 | -3.68% | -5.17% | 0.52x | 1.37x | $-233.49 Million |
| 2017 | -1.38% | -2.48% | 0.40x | 1.38x | $-206.63 Million |
| 2018 | -12.60% | -17.11% | 0.43x | 1.70x | $-339.77 Million |
| 2019 | -11.39% | -14.54% | 0.45x | 1.74x | $-296.01 Million |
| 2020 | -31.45% | -37.34% | 0.39x | 2.16x | $-459.75 Million |
| 2021 | -10.49% | -13.12% | 0.47x | 1.70x | $-265.28 Million |
| 2022 | -7.14% | -8.44% | 0.45x | 1.90x | $-207.01 Million |
| 2023 | 1.37% | 1.52% | 0.47x | 1.90x | $-110.22 Million |
| 2024 | 4.79% | 5.04% | 0.50x | 1.90x | $-68.79 Million |
Industry Comparison
This section compares LivaNova PLC's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LivaNova PLC (LIVN) | $1.16 Billion | -21.16% | 1.21x | $3.18 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |